Acquisition / mergerNotableFiled on BSE ·

Anupam Rasayan board approves acquisition of up to 74.20% control of Bliss GVS Pharma

Anupam Rasayan India · Chemicals & Petrochemicals

Arthneeti Research DeskPublished 1 min read
74.20%Acquisition / merger

Key highlights

  • Anupam Rasayan to acquire 4,58,03,024 Bliss GVS shares (43.30%) from sellers at Rs 299 per share, aggregating Rs 1369,51,04,176, subject to closing under the SPA
  • Call option on up to 51,81,571 residual shares (4.90%) at the SPA price on the Closing Date; shares not acquired then may be acquired later at prevailing market price, not below Rs 299
  • Open offer for up to 2,77,26,848 shares (26.00% of expanded share capital) at Rs 299 per share; Bliss GVS turnover Rs 1000,64,26,000 for 2025-2026

Why it's rated notable: amount is ₹500 crore or more

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Announcement under Regulation 30 (LODR)-Acquisition

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Anupam Rasayan India

Other acquisition / merger filings this fortnight

All acquisition / merger filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.